Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Liquidia Technologies ( (LQDA) ) has shared an announcement.
On June 23, 2025, Liquidia Corporation announced receiving an additional $50 million in funding under its agreement with Healthcare Royalty Partners IV, following the first commercial sale of YUTREPIA after the U.S. District Court denied an injunction request by United Therapeutics. This funding will support Liquidia’s launch execution, clinical pipeline advancement, and manufacturing expansion, reinforcing its financial position and ability to achieve profitability. The company has received $175 million of the potential $200 million funding, with an additional $25 million available upon achieving certain sales milestones.
The most recent analyst rating on (LQDA) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Liquidia Technologies stock, see the LQDA Stock Forecast page.
Spark’s Take on LQDA Stock
According to Spark, TipRanks’ AI Analyst, LQDA is a Neutral.
Liquidia’s stock score is primarily constrained by its significant financial challenges, including persistent losses and high leverage. While recent corporate events and strategic advancements offer positive prospects, the company’s financial instability and bearish market sentiment weigh heavily on its overall score.
To see Spark’s full report on LQDA stock, click here.
More about Liquidia Technologies
Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases. The company specializes in the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT® Technology. Liquidia’s key product, YUTREPIA™ (treprostinil) inhalation powder, is approved for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Average Trading Volume: 1,913,028
Technical Sentiment Signal: Buy
Current Market Cap: $1.13B
Find detailed analytics on LQDA stock on TipRanks’ Stock Analysis page.